Locanabio, Inc.

While 2023 saw several cell and gene therapy approvals that were genuine scientific and clinical breakthroughs, many smaller companies in the sector bore the brunt of the ongoing biopharma downturn. M

“Biomedical innovation is at its golden age, and scientific innovation will continue to be strong,” declared Søren Møller , managing partner at Novo Seeds , the life science start-up financing arm o

Biopharmaceutical companies developing therapies for neurological diseases are in the midst of a boom, not only in terms of novel approaches to treating intractable diseases but also in terms of attra